Skip to main content
. 2018 Aug 14;11:4877–4891. doi: 10.2147/OTT.S169823

Table 3.

HR with 95% CI of lncRNA expression in GC

lncRNA Number of articles Included articles HR 95% CI Figure P-value Heterogeneity (Higgins I2 statistic) Total patients
High AFAP1-AS1 2 3, 4 2.47 1.41–4.30 2 <0.01 I2=32.7%, P=0.22 178
High ANRIL 2 9, 10 1.68 1.16–2.43 2 <0.01 I2=0.0%, P=0.84 220
High CASC15 2 18, 19 1.99 1.21–3.28 2 <0.01 I2=0.0%, P=0.54 148
High CCAT2 2 21, 22 2.17 1.53–3.09 2 <0.01 I2=0.0%, P=0.76 193
High GAPLINC 2 32, 33 1.49 1.18–1.89 2 <0.01 I2=0.0%, P=0.76 123
High H19 4 29, 36–38 1.51 1.05–2.17 2 0.03 I2=64.1%, P=0.04 643
High HOTAIR 9 41–49 1.93 1.53–2.43 3 <0.01 I2=14.0%, P=0.31 794
High HOTTIP 3 50–52 1.57 1.20–2.05 6 <0.01 I2=0.2%, P=0.37 540
High LINC00673 2 61, 62 2.47 1.45–4.20 6 <0.01 I2=0.0%, P=0.89 152
High MALAT1 4 43, 72–74 1.70 1.33–2.18 6 <0.01 I2=29.7%, P=0.23 496
Low MEG3 2 76, 77 1.96 1.17–3.28 6 0.01 I2=0.0%, P=0.95 206
High PANDAR 2 86, 87 3.11 2.72–3.55 6 <0.01 I2=0.0%, P=0.79 246
High PVT1 2 89, 90 2.17 1.31–3.60 6 <0.01 I2=0.0%, P=0.87 191
High Sox2ot 2 96, 97 2.30 1.52–3.46 7 <0.01 I2=0.0%, P=0.35 287
Low SPRY4-IT1 2 98, 99 1.42 0.48–4.22 7 0.53 I2=71.4%, P=0.06 236
High UCA1 4 101–104 1.73 1.12–2.68 7 0.01 I2=45.5%, P=0.14 399
High XIST 2 107, 108 1.89 1.38–2.59 7 <0.01 I2=23.4%, P=0.25 204
High ZEB1-AS1 2 109, 110 2.07 1.67–2.56 7 <0.01 I2=0.0%, P=0.62 831
High ZFAS1 2 111, 112 2.51 1.34–4.69 7 <0.01 I2=0.0%, P=0.93 158

Abbreviations: AFAP1-AS1, AFAP1 antisense RNA 1; ANRIL, CDKN2B antisense RNA 1; CASC15, cancer susceptibility 15; CCAT2, colon cancer associated transcript 2; GAPLINC, gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA; GC, gastric cancer; H19, H19, imprinted maternally expressed transcript; HOTAIR, HOX transcript antisense RNA; HOTTIP, HOXA distal transcript antisense RNA; LINC00673, long intergenic non-protein coding RNA 673; lncRNA, long noncoding RNA; MALAT1, metastasis-associated lung adenocarcinoma transcript 1; MEG3, maternally expressed 3; PANDAR, promoter of CDKN1A antisense DNA damage activated RNA; PVT1, Pvt1 oncogene; Sox2ot, SOX2 overlapping transcript; SPRY4-IT1, SPRY4 intronic transcript 1; UCA1, urothelial cancer associated 1; XIST, X inactive specific transcript; ZEB1-AS1, ZEB1 antisense RNA 1; ZFAS1, ZNFX1 antisense RNA 1.